COVID-19 Response (TI): antivrial & Inflammation Controlling Therapeutic Drug Clinical Evaluation
$10,000,000.00
Grant Value
2021-22
Fiscal Year
Description
Clinical development of LAU-7b antiviral and inflammation-controlling therapy for COVID-19 infection.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Grant Details
Recipient
Laurent Pharmaceuticals Inc.
Operating as: Laurent Thrapeutiques
Location
Montreal, QC H3A 2R7
Agreement Details
Number: 958708
Reference: 172-2021-2022-Q4-958708
Timeline
Start: Oct. 1, 2020
End: Dec. 31, 2022
Program
Industrial Research Assistance Program Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …
Sector
Professional, scientific and technical services (541710)
Your Contribution
Calculate how much you personally contributed to this grant through your taxes.
Calculate My Share